| Literature DB >> 36207701 |
Cheng Xu1, Yijie Zhu2,3,4, Lianlian Wu2,3,4, Shaoqing Lei5, Zhongyuan Xia6, Honggang Yu2,3,4, Jun Liu2, Fang Zhou1, Qiutang Xiong2,3,4, Shanshan Wang1, Shanshan Cui1, Xu Huang2,3,4, Anning Yin2,3,4, Tingting Xu1.
Abstract
BACKGROUND: Sedative gastrointestinal endoscopy is extensively used worldwide. An appropriate degree of sedation leads to more acceptability and satisfaction. Artificial intelligence has rapidly developed in the field of digestive endoscopy in recent years and we have constructed a mature computer-aided diagnosis (CAD) system. This system can identify the remaining parts to be examined in real-time endoscopic procedures, which may help anesthetists use anesthetics properly to keep patients in an appropriate degree of sedation. AIMS: This study aimed to evaluate the effects of the CAD system on anesthesia quality control during gastrointestinal endoscopy.Entities:
Keywords: Anesthesia; Artificial intelligence; Endoscopy
Mesh:
Substances:
Year: 2022 PMID: 36207701 PMCID: PMC9540709 DOI: 10.1186/s12871-022-01796-1
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.376
Fig. 1Clinical Usage of CAD system. Working scene in clinical. Clinical use of CAD system is shown in the center of this figure. Implications of this system are shown on two sides of this figure, and we can see the spending time and process of endoscopic examinations
Fig. 2Summary chart
Fig. 3Flow diagram
Baseline of patients’ characteristics. Data is presented as Mean ± SD (standard deviation, SD) or numbers
| Characteristics | CAD Group ( | The Control Group ( | |
|---|---|---|---|
|
| 24/16/36 | 26/18/34 | 0.892 |
|
| 45.99 ± 12.79 | 47.82 ± 13.04 | 0.380 |
|
| |||
| Male | 35 (46.05) | 35 (44.87) | 0.883 |
|
| 22.96 ± 3.17 | 22.61 ± 3.14 | 0.502 |
|
| 59/16/1 | 63/13/2 | 0.685 |
|
| |||
| Outpatient | 68 (89.47) | 67 (85.90) | 0.500 |
|
| |||
| Screening/ Symptomatic/ Surveillance | 10/46/20 | 12/45/21 | 0.909 |
|
| |||
| Hypertension | 9 (11.84) | 10 (12.82) | 0.854 |
| Diabetes | 2 (2.63) | 1 (1.28) | 0.982 |
| Ischemic heart disease | 0 (0.00) | 4 (5.13) | 0.135 |
| Cerebral vascular insuffificiency | 2 (2.63) | 2 (2.56) | 1.000 |
| Arrhythmia | 0 (0.00) | 0 (0.00) | |
| COPD | 3 (3.95) | 1 (1.28) | 0.594 |
|
| 25 (32.89) | 30 (38.46) | 0.471 |
|
a
| |||
| Reflux Esophagitis | 4 | 5 | - |
| Barrett Esophagus | 3 | 4 | - |
| Chronic Superficial Gastritis | 23 | 19 | - |
| Chronic Atrophic Gastritis | 14 | 15 | - |
| Gastric Polyp | 10 | 8 | - |
| Peptic Ulcer | 4 | 6 | - |
| Colorectal Polyp | 15 | 13 | - |
| Colorectal Erosion | 4 | 5 | - |
| Other Dieases | 19 | 14 | - |
aOne patient can have diverse endoscopic diagnosis
Outcomes of examinations. Data is presented as Mean ± SD (standard deviation, SD) or numbers
| Patients’ parameters | CAD Group ( | the Control Group ( | |
|---|---|---|---|
|
| 1.02 ± 0.31 | 1.05 ± 0.30 | 0.551 |
|
| |||
| Procedure time (EGD), min (Mean ± SD) | 4.55 ± 1.15 | 4.12 ± 0.95 | 0.165 |
| Procedure time (colonoscopy), min (Mean ± SD) | 15.02 ± 8.18 | 15.42 ± 5.71 | 0.872 |
| Procedure time (EGD + colonoscopy), min (Mean ± SD) | 22.46 ± 6.89 | 22.24 ± 9.76 | 0.914 |
|
| 2.73 ± 2.16 | 4.73 ± 3.34 | **0.000 |
|
| 4.01 ± 2.40 | 6.55 ± 3.80 | **0.000 |
|
| 190.07 ± 50.15 | 205.58 ± 58.08 | 0.080 |
|
| |||
| aRamsay1, n (%) | 50 (65.79) | 33 (42.31) | **0.003 |
| aRamsay2, n (%) | 75 (98.68) | 65 (83.33) | **0.001 |
| aRamsay3, n (%) | 76 (100.00) | 77 (98.72) | 0.242 |
|
b
| |||
| Patient Satisfaction (Mean ± SD) | 4.54 ± 0.50 | 4.04 ± 0.49 | **0.000 |
| Anesthetist Satisfaction (Mean ± SD) | 4.21 ± 0.61 | 3.55 ± 0.67 | **0.000 |
| Endoscopist Satisfaction (Mean ± SD) | 4.24 ± 0.53 | 3.79 ± 0.54 | **0.000 |
a Numbers of RSS scores between 2 to 4. Ramsay1 for sedation scoring immediately after procedure, Ramsay2 for sedation scoring 5 min after entering recovery room and Ramsay3 for sedation scoring when leaving the recovery room. b Quantization of satisfaction was based on 5-point Likert scales. **p value < 0.01. EGD, esophagogastroduodenoscopy
Fig. 4Vital signs at six moments of two groups. A Comparison MAP between two groups. B Comparison HR between two groups. C Comparison SpO2 between two groups. D Comparison RR between two groups. *p value < 0.05. MAP, mean arterial pressure. HR, heart rate. RR, respiratory rate
Safety analysis. Adverse events and use of other medications (n). Data is expressed as numbers, (%) of patients
| CAD Group ( | The Control Group ( | ||
|---|---|---|---|
|
|
|
|
|
| Chocking cough | 4 (5.26) | 14 (17.95) | *0.014 |
| Hiccup | 5 (6.58) | 5 (6.41) | 1.000 |
| Moving | 1 (1.32) | 5 (6.41) | 0.224 |
| Hypertension | 0 | 0 | - |
| Arrhythmia | 2 (2.63) | 1 (1.28) | 0.982 |
| Hypoxemia | 1 (1.32) | 1 (1.28) | 1.000 |
| Hypotension | 1 (1.32) | 1 (1.28) | 1.000 |
|
|
|
|
|
| Dizziness | 0 | 0 | - |
| Nausea | 0 | 1 (1.28) | 1.000 |
| Respiratory depression | 0 | 0 | - |
| Dysphoria | 0 | 0 | - |
| Hypoxemia | 1 (1.32) | 1 (1.28) | 1.000 |
|
|
|
|
|
| Phenylephrine | 1 (1.32) | 1(1.28) | 1.000 |
| Atropine | 0 | 1(1.28) | 1.000 |
| Dopamine | 0 | 1 (1.28) | 1.000 |
| Methoxamine hydrochloride | 1 (1.32) | 0 | 0.494 |